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AggregationThe protein alpha-synuclein is considered to play a major role in the etiology of Parkinson's disease. Because
it is found in a classic amyloid ﬁbril form within the characteristic intra-neuronal Lewy body deposits of the
disease, aggregation of the protein is thought to be of critical importance, but the context in which the pro-
tein undergoes aggregation within cells remains unknown. The normal function of synucleins is poorly un-
derstood, but appears to involve membrane interactions, and in particular reversible binding to synaptic
vesicle membranes. Structural studies of different states of alpha-synuclein, in the absence and presence of
membranes or membrane mimetics, have led to models of how membrane-bound forms of the protein
may contribute both to functional properties of the protein, as well as to membrane-induced self-assembly
and aggregation. This article reviews this area, with a focus on a particular model that has emerged in the
past few years. This article is part of a Special Issue entitled: Protein Folding in Membranes.n Folding in Membranes.
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Alpha-synuclein (α-synuclein, aS) is a small (140-residue,
14.5 kDa), soluble presynaptic protein that is highly conserved in ver-
tebrates and has been implicated in Parkinson's disease (PD). Several
mutations (A53T, A30P, and most recently E46K) in the human aS
gene, designated SNCA, [1–3] as well as duplications and triplications
of the gene [4,5] have been found to be associated with rare familial
Parkinson's. In addition, Lewy bodies, protein deposits that are
found intra-neuronally in Parkinson's brains, are composed largely
of β-sheet-rich alpha-synuclein amyloid ﬁbrils [6]. In light of these
ﬁndings, much effort has been focused on clarifying the links between
alpha-synuclein and Parkinson's.
Since the original discovery of a synuclein protein in the electric
organ synapses of the electric ray Torpedo californica [7], a relation-
ship between synucleins and membranes has been apparent. In
both ray and rat, aS was found to localize to the presynapticmembrane as well as to a region of the nuclear envelope (hence the
name synuclein). Furthermore, the N-terminal domain of aS includes
7 imperfect 11-residue repeats, each containing a variant of the con-
sensus 6-residue sequence KTKEGV, which are similar to repeats
found in the exchangeable apolipoproteins and are consistent with
a class A2 amphipathic alpha helices [8] suggesting a lipid-binding ac-
tivity for the N-terminal domain. aS was shown to associate with syn-
aptic vesicle preparations [9,10], and to bind to synthetic
phospholipid vesicles containing negatively-charged phospholipids
[11,12], although the association was found to be relatively weak,
an observation that was subsequently conﬁrmed in more detail
[13,14].
Presently, the normal function of alpha-synuclein remains poorly
understood, although it has been linked with synaptic plasticity [15]
and learning [8], neurotransmitter release [16,17] and maintenance
of synaptic vesicle pools [18,19]. The function of aS may be linked to
its interesting structural properties. In dilute aqueous solutions in
vitro, synuclein adopts a natively unfolded, or intrinsically disordered,
structural ensemble [20]. However, even in this generally unstruc-
tured form, the N-terminal lipid-binding domain of aS displays a
slight preference for helical structure [21]. Upon binding to negatively
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this N-terminal domain adopts a highly helical structure [11,21].
The micelle-bound form of aS consists of two non-contacting antipar-
allel helices in the N-terminal domain with a short break around resi-
dues 38–44, and a ﬂexible conformation in the C-terminal domain
[22–27].
The aggregation mechanisms and propensities of aS have been
studied in detail, but a consensus view of the aggregation mechanism
still eludes researchers. The PD-linked mutations A30P and A53T both
increase the rate of aS aggregation in vitro [28,29], although A53T aS
forms ﬁbrils faster than wild-type while A30P aS forms ﬁbrils more
slowly [30], suggesting that it is the acceleration of oligomerization,
and not mature ﬁbril formation, which may be the common feature
of PD-linked mutants. E46K aS was also found to ﬁbrillize more rapid-
ly [31]. Since A30P was found to reduce local helical propensity and
A53T to increase local β-sheet propensity, it was postulated that
this change in local peptide properties was responsible for the in-
creased likelihood to form β-sheet-rich aggregates in those mutants
[32].
An additional hypothesis suggested that long-range interactions
involving the central hydrophobic NAC region of alpha-synuclein
may inﬂuence oligomerization of the protein [32]. Early NMR residual
dipolar coupling (RDC) data suggested that C- to N-terminal long-
range interactions were lost in the A30P and A53T mutants [33],
exposing the NAC region. However, subsequent studies indicated
that the E46K mutation increases such contacts, and that they are
unaffected by the A30P and A53T mutations. Other conditions that
increase the compactness of regions of the protein also lead to en-
hanced aggregation [34] whereas variants or conditions that reduce
long-range interactions are associated with reduced aggregation
[35,36], Thus, it seems that long-range contacts may not be protective
against aS aggregation and might even facilitate the process [37].
Membrane interactions have also been implicated in alpha-
synuclein aggregation. The rate of ﬁbrillization of wild-type aS was
found to be increased in the presence of lipids and detergents
[38–42], at least under some circumstances. The detailed mechanisms
by which membranes enhance the aggregation of aS remain unclear,
but a potential role for helical intermediates in this process has
been suggested both by recent NMR studies of vesicle-binding
modes of aS and disease-linked aS mutants [43,44] as well as by a
study of triﬂuoroethanol (TFE) induced aS aggregation [45].
2. Membrane-associated folded and functional states
Understanding the normal function of alpha-synuclein is impor-
tant for a number of reasons, including an appreciation of its normal
role in synaptic (and possibly other) pathways, a better knowledge
of different contexts in which to potentially intervene in the behavior
of the protein in vivo, and the remaining possibility that alterations in
the normal function of the protein may play a role in PD, highlighted
by recent work showing that removal of all synuclein family members
in mice leads to an age-dependent neurodegeneration and a de-
creased life span [17]. The normal membrane-binding modes of
alpha-synuclein are considered to play a critical role in the protein's
function, making studies of membrane-bound states of considerable
interest. Of course, the possible role for membranes in facilitating aS
aggregation in vivo adds to the importance of understanding how
the protein interacts with membranes.
Subsequent to early studies using optical spectroscopies such as
circular dichroism (CD), which demonstrated a large-scale disorder-
to-helix transition in aS upon binding of the protein to vesicles of dif-
ferent types [11,12,46], NMR studies of the protein in the presence of
membrane-mimetic sodium dodecyl sulfate (SDS) micelles revealed
that the N-terminal lipid-binding domain of the protein (consisting
approximately of residues 1–100) adopts a helical structure made
up of two curved antiparallel helices connected by an extended linkerof residues 38 to 44 [22–24]. Based on NMR chemical shifts of amide
resonances, as increasing concentrations of detergent are added to
solutions containing aS the protein folds into the broken-helix confor-
mation through a third, intermediate state, which may consist of
more than one aS molecule bound to a micelle or a non-helical con-
formation [24]. Evidence for such an intermediate has also been re-
cently provided by small angle x-ray scattering (SAXS) in
combination with other methods [47].
In the micelle-bound broken-helix state, the region from alanine
30 to valine 37 was found to have higher mobility as measured by
RDCs [24] and lower helical propensity as measured by the difference
of Cα chemical shift from the random coil value [22–24]. These data
are consistent with some degree of instability and/or helix fraying
at the C-terminal end of the ﬁrst helix. There is also an apparent
kink or instability in the second of two helices around position 65.
Both of the two micelle-bound helices remain on the surface of the
micelle, and no evidence of any trans-micelle orientations were ob-
served in NMR paramagnetic relaxation enhancement (PRE) studies
[27]. The same studies indicated that the helices may penetrate as
deep as the C3 or C4 carbons of the detergent acyl chain, consistent
with an estimate, based on an evaluation of the electrostatic surface
potential of alpha-synuclein, that the apolar faces of the helices that
interact with the micelle surface may insert past the charged head-
groups [24]. Meanwhile, many of the positively-charged sidechains
are facing outward from the helices, possibly lying on the surface of
the micelle and interacting with the negatively charged headgroups.
While an SDS micelle has a diameter of around 5 nm, synaptic ves-
icles are approximately ten times larger. Thus, the relevance of the
broken-helix micelle-bound structure of aS to the conformation
adopted by the protein when bound to synaptic vesicles has remained
controversial. It was noted that the small size of the spheroidal mi-
celles may dictate the broken-helix or “horseshoe” conformation by
requiring the protein to adhere to the micelle surface [22]. Indeed,
studies using pulsed ESR (electron spin resonance) distance measure-
ments demonstrated that increasing the size of the micelle to which
the protein was bound leads the two helices to splay further apart
[26], supporting the notion that micelle topology profoundly inﬂu-
ences the relative arrangement of the two micelle-bound helices.
The protein-vesicle complex is too large for the type of detailed
NMR studies that were used to characterize the micelle-bound state,
although an initial study was able to determine that in both contexts
(micelle- and vesicle-bound) the same regions of the protein be-
comes helical (the N-terminal lipid-binding domain) and the same
regions remain disordered (the acidic C-terminal tail consisting of
the C-terminal 40 residues of the protein) [21]. More recently pulsed
dipolar ESR measurements of long intramoleculear distances (up to
90 Å) in aS bound to vesicles as well as bicelles (disk-shaped lipid bi-
layer structures comprised of long-chain phospholipids surrounded
by a layer of short-chain detergent molecules [48]) have been used
to characterize the conformation of vesicle-bound synuclein and the
lipid-binding domain of the protein was found to adopt a single ex-
tended helix, in which the two separate helices of the micelle-
bound broken-helix state fuse into one longer helix, with the linker
region converting from an extended to a helical conformation
[49,50]. ESR studies combining shorter distance measurements with
computational modeling reached a similar conclusion [51], as did
complementary studies using single-molecule Förster resonance en-
ergy transfer (smFRET) distance measurements [52,53].
Despite these observations that aS adopts the extended-helix con-
formation when bound to lipid vesicles, it appears that the micelle-
bound structure of aS remains relevant to the physiological context
of synaptic vesicles and the presynaptic membrane. Several studies
have noted that the broken-helix state can be observed even in the
presence of lipid vesicles [54,55] while others have noted that
under some circumstances both states (extended- and broken-
helix) can co-exist in the context of vesicles [49,56,57] suggesting
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primary sequence of the protein. Based on our initial observations
of the broken- and extended-helix states, we proposed a model in
which the uniquely apposedmembrane topology of fusing or budding
vesicles could provide a scaffold for the broken-helix conformation of
alpha-synuclein to act as a bridge between different membranes
[49,58]. In this model, one of the two helices of aS would bind to
the plasma membrane, and the other to a docked or budding synaptic
vesicle. The protein could function to anchor the vesicle to the mem-
brane or even possibly to sense the extent of budding/fusion. This
model was inspired in part by observations that synuclein expression
can lead to a clustering of vesicles in yeast [59] and to a stabilization
of docked vesicles in chromafﬁn cells [60]. Several reports suggesting
that the N-terminal and C-terminal regions of the lipid-binding do-
main of aS exhibit different membrane-binding afﬁnities [43,61,62]
are also consistent with a potential bridging function for the protein.
The observation that aS interacts with and inhibits phospholipase
D (PLD), which catalyzes the hydrolysis of phosphatidylcholine to
phosphatidic acid [63] also suggests that placing synuclein at the
site of docked vesicles could serve to inﬂuence the membrane remo-
deling processes involved in vesicle fusion or budding (although PLD
regulation by aS has been contested in recent work [64]). PLD is im-
plicated in the regulation of secretory vesicle budding or fusion
through its generation of phosphatidic acid [65,66], which can play
a role in modulating membrane curvature and also regulates
phosphatidylinositol-4-phosphate 5-kinase activity [67]. The interac-
tion of aS with PLD appears to require the helical, membrane-bound
form of aS and to involve both the helical domain and the more highly
disordered C-terminal tail [68]. Because PLD is likely to act on the
plasma membrane and is not known to be associated with synaptic
vesicles, regulation of PLD activity by aS is consistent with the idea,
depicted in our model, that aS is able to contact both the vesicle and
plasma membranes in some contexts.
A recent ESR study of the interconversion between the broken-
and extended-helix conformations of aS in the presence of deter-
gents showed that the detergent to protein concentration ratio de-
termines which conformation is adopted by the protein, with
higher populations of the extended-helix conformation observed
at ratios above ~500:1 [50]. The extended-helix state could be ob-
served even at detergent concentrations below those required for
cylindrical micelle formation in the absence of protein, indicating
that the protein can alter micelle behavior and topology. This ﬁnd-
ing suggests that aS is not just a passive adapter to a preconﬁ-
gured membrane topology, but may itself inﬂuence the topology
of the membranes to which it binds. A membrane bending or
remodeling activity of alpha-synuclein has been documented by
others [69,70] supporting a potential role for this activity of aS in
the membrane remodeling required for vesicle fusion or budding.
Indeed, a recent report shows that aS may interact directly with
SNARE proteins and may inﬂuence the efﬁciency of synaptic vesi-
cle exocytosis [17]. The protein has also been implicated in endo-
cytic pathways [71].
In addition to the above, structure-basedmodel of alpha-synuclein
function, others have been proposed. Various forms of aS, including
oligomeric or protoﬁbrillar species, have been reported to permeabi-
lize membranes [72], suggesting a potential function for the protein
as some kind of pore or channel. Indeed, a recent study provides evi-
dence of channel formation by aS even as a monomer [73] and pro-
poses a model of helical aS monomers partitioning from the
membrane surface into a hairpin transmembrane topology in the
presence of a voltage across the membrane, such as that generated
in the neuron during transmission of an action potential.
Beyond its regulation of PLD, aS has been reported to preferential-
ly interact with several proteins in its lipid-bound form, among them
endosulﬁne-α and its close relatives the cAMP-regulated phospho-
proteins ARPP-19 and ARPP-16 [74]. These proteins are thought tofunction in dopamine and other signaling networks [75], and are
also regulators of protein phosphatases [76].
While the N-terminal ~100 residues of aS are usually considered
to constitute the lipid-binding domain of the protein, the acidic C-
terminal tail may also play a role in membrane-binding, as well as
other aspects of synuclein function. In the micelle-bound structure,
the C-terminal tail was found to be mostly disordered; however,
there was some heterogeneity in the NMR properties [24,27] and a
subsequent study also reported a weak vesicle interaction for residues
in the C-terminal tail, which was associated with shift between trans
and cis X-Pro peptide bonds among several proline residues and the
ensuing increased lipid binding of the cis-containing conformations
[43]. Interestingly, a recent report indicates that nitration of tyrosines
in the C-terminal tail of aS alters its afﬁnity for membranes [77], again
suggesting some role (either direct or indirect) for the C-terminal
tail in modulating aS membrane interactions. In general, however,
the C-terminal tail of aS (as well as those of the closely related family
members β- and γ-synuclein) is thought to function as a protein-
protein interaction motif [78], as illustrated by its role in interactions
with both PLD and the neuronal v-SNARE protein synaptobrevin 2
[17], and other post-translational modiﬁcations such as phosphoryla-
tion at serine 129 or serine 87 have not thus far been shown to alter
membrane binding [36,79].
3. Membrane-induced aggregation
Lipids, fatty acids and detergents have been found to accelerate aS
ﬁbrillization under various circumstances [38–42,80–83]. A critical
factor seems to be the ratio of protein to lipid or detergent [40,41],
with higher ratios (low concentrations of lipid or detergent) driving
aggregation, while lower ratios (high concentrations of lipid or deter-
gent) tend to prevent aggregation [84,85]. This observation suggests
that one mechanism by which lipids or lipid-like molecules may facil-
itate aS aggregation is by conﬁning the protein to a small and/or two
dimensional surface (the surface of a vesicle or micelle), thereby in-
creasing the effective concentration and driving aggregation through
mass action [86,87]. Some support for this scenario is provided by the
observation that in the case of detergents, aggregation is enhanced
when the detergent:protein ratio falls below the number of detergent
molecules required to form a single micelle, and inhibited once there
is sufﬁcient detergent to insure that each protein can be accommo-
dated on a separate micelle (unpublished data and [24]). However,
this effect is difﬁcult to verify directly, and additional factors such as
potentially different diffusion rates on a membrane surface or in solu-
tion [88,89] must be taken into account as well.
An additional potential contribution to membrane-induced aS ag-
gregation may arise from the conformational changes that are in-
duced in the protein by its membrane interactions, and that can
favor intermolecular interactions leading to aggregation. Support for
this model comes from observations that at concentrations that
favor aggregation, detergents also appear to induce intermediate con-
formations of aS [24,47,80,90].
Recently, we published a study aimed at assessing the role of
membrane-induced structural changes, versus surface-induced mass
action effects. We used ﬂuorinated alcohols to decouple conforma-
tional changes similar to those induced by membranes from the pro-
cess of binding to a surface. Several previous studies demonstrated
that such cosolvents enhanced the propensity of aS to aggregate
[91,92] and could also be used to model the protein's membrane in-
teractions [93]. Working at very low protein concentrations to main-
tain aS in a monomeric state and preclude aggregation, we used CD
spectroscopy to analyze the changes induced in aS by varying concen-
trations of TFE, and to correlate these effects with changes in aggrega-
tion propensity [45]. It was ﬁrst shown that at very low (below a few
percent by volume) and very high (above 30% by volume) TFE con-
centrations, aggregation of aS is inhibited, just as it is in the presence
Fig. 1. Summary of some of the models presented in this manuscript for the membrane-induced structure, function and aggregation of the Parkinson's disease linked protein
alpha-synuclein. Poorly structured protein regions are depicted as solid lines, while helical regions are depicted as ﬁlled bars or cylinders. Membrane bilayers are indicated as
double black lines with hashes. The unbound, intrinsically disordered state of aS is depicted as existing in equilibrium between less compact and more compact conformations,
which are also in equilibrium with the vesicle-bound extended-helix state. The latter can convert to the broken-helix state upon approach of the vesicle to another membrane,
such as the pre-synaptic plasma membrane. Transitions between these conformations, which are all considered to occur as part of the normal function of the protein, are in-
dicated by black double arrows. The potential activity of the broken helix state (possibly through the action of the linker region) in modulating membrane properties during
membrane fusion is indicate by the green color of the linker region and the dotted lines between the vesicle and plasma membranes. Either the extended- or broken-helix
states may be able to convert to a membrane-bound partially helical intermediate by the release of the C-terminal region of the lipid-binding domain from the membrane
surface. Intermolecular association of these intermediates, driven by the membrane-associated N-terminal helices, may bring the disordered regions into close proximity, fa-
cilitating intermolecular beta-sheet formation leading to amyloid oligomer and ﬁbril formation. These transitions, which are considered to occur as part of the pathological
behavior of the protein, are indicated by orange double arrows.
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intermediate TFE concentrations, aS aggregation becomes very efﬁ-
cient, just as it is at intermediate concentrations of lipids or deter-
gents. The results then showed that a distinct and partially helical
aS intermediate was formed at intermediate TFE concentrations, and
that the maximal population of the intermediate state correlated
with the maximal aggregation propensity induced by the cosolvent.
This result strongly suggests that the helical structure in the interme-
diate state plays a role in driving the aggregation of the protein, even
in the case where no mass action effect is present. A similar
conclusion was achieved based on studies of aS in the presence of
combinations of crowding agents with other reagents, including or-
ganic cosolvents, that favor partial folding of aS [94].
A reconstruction of the far-UV CD spectrum for this TFE-induced
partially folded intermediate demonstrated that approximately 20–
30 residues are likely to adopt a helical structure within the context
of the intermediate, and an analysis of the PD-linked mutations in
the protein revealed that only the A30P mutation affected the spec-
trum of the intermediate, causing a signiﬁcant decrease in its helicity
and suggesting that position 30 is included in the helical structure.
The original study of helical propensities in the free state of aS [21]
noted that the N-terminal 30–40 residues exhibited the strongest in-
trinsic propensity for helical structure and suggested that this region
might fold ﬁrst upon association of the protein with membranes. A
recent study of synuclein peptide fragments binding to lipids sup-
ports this assertion [95]. Furthermore, several studies have suggested
the existence of partially folded membrane-bound intermediates, in
which the N-terminal region is folded and helical, with the remainder
of the lipid-binding domain remains unbound [43,44,61]. Thus, it ap-
pears that the partially helical intermediate formed in the presence of
TFE, which efﬁciently drives the aggregation of the protein, may have
a corresponding membrane-induced intermediate where the N-
terminal region of the protein is bound and helical, but the remainder
of the lipid-binding domain remains disordered. Although themembrane-bound intermediate might be expected to bury its hydro-
phobic face at the protein-membrane interface, the relatively low af-
ﬁnity of synuclein-membrane interactions may favor the formation
of protein–protein interactions when two membrane-bound inter-
mediates encounter each other. Thus, this intermediate state could
drive self-association of the protein on the membrane surface (per-
haps in a manner further enhanced by mass action effects as dis-
cussed above), bringing the more C-terminal unstructured regions
into close proximity and facilitating the nucleation of inter-molecular
beta-sheet structure and the eventual formation of amyloid oligomers
and ﬁbrils. Notably, models invoking similar roles for helical interme-
diates in promoting the aggregation of other amyloidogenic proteins
have been gaining support in recent years [96].
4. Conclusions
Some of the models for membrane-induced folding, function and
aggregation of aS are summarized in Fig. 1. The highly disordered
free state of the protein is proposed to exist in equilibrium with the
vesicle-bound extended-helix form of the protein, which can inter-
convert into the broken-helix state upon the close approach of a syn-
aptic vesicle to the plasma membrane. The broken-helix form can
function as a structural support or sensor for docked vesicles, but
may also play an active role in vesicle fusion either by regulating
the activities of other proteins such as PLD or synaptobrevin, or by di-
rectly inﬂuencing the properties of the membranes involved in order
to inﬂuence the fusion process. Under different circumstances, such
as when the protein ﬁrst begins to fold upon binding to membranes,
or upon release of the C-terminal region of the extended-helix con-
formation from the membrane surface, or upon release of the second
helix of the broken-helix state from the membrane-bridging conﬁgu-
ration, an intermediate state may be formed in which the N-terminal
region remains bound and helical, while the C-terminal region of the
lipid-binding domain is unstructured. The helical regions of such
1017I. Dikiy, D. Eliezer / Biochimica et Biophysica Acta 1818 (2012) 1013–1018intermediates may drive their intermolecular interactions, bringing
the disordered C-terminal regions into close proximity and facilitat-
ing their aggregation into the beta-sheet rich aggregates characteris-
tic of PD. While all aspects of these models require extensive testing
before they can be considered to reﬂect the actual behavior of the
protein in vivo, they are consistent with many existing observations
regarding the properties and potential functions of aS.References
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